Trials / Completed
CompletedNCT00396916
Hybrid PET/CT in Cancer Patients
The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PET/CT imaging |
Timeline
- Start date
- 2004-12-01
- First posted
- 2006-11-08
- Last updated
- 2007-04-11
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00396916. Inclusion in this directory is not an endorsement.